FLUTEMETAMOL IS INDICATED FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT WHO ARE BEING EVALUATED FOR ALZHEIMER'S DISEASE (AD) AND OTHER CAUSES OF COGNITIVE DECLINE.
RECOMMENDED DOSE FOR FLUTEMETAMOL IS 185 MEGABECQUERELS (MBQ) [5 MILLICURIES (MCI)] IN A MAXIMUM DOSE VOLUME OF 10 ML, ADMINISTERED AS A SINGLE INTRAVENOUS BOLUS WITHIN 40 SECONDS. THE MAXIMUM MASS DOSE IS 20 MICROGRAMS. FOLLOW THE INJECTION WITH AN INTRAVENOUS FLUSH OF 5 TO 15 ML OF 0.9% STERILE SODIUM CHLORIDE INJECTION.
LIMITATIONS OF USE
" A POSITIVE FLUTEMETAMOL SCAN DOES NOT ESTABLISH A DIAGNOSIS OF AD OR OTHER COGNITIVE DISORDER.
" SAFETY AND EFFECTIVENESS OF FLUTEMETAMOL HAVE NOT BEEN ESTABLISHED FOR:
" PREDICTING DEVELOPMENT OF DEMENTIA OR OTHER NEUROLOGIC CONDITION.
" MONITORING RESPONSES TO THERAPIES.